Search

everythinglearnresearchcommunity

for

Search:↓

RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.

The conversation discusses a hair loss treatment regimen including oral dutasteride, oral minoxidil, tadalafil, and the recent addition of RU58841. The user shares experiences with these treatments, noting significant hair regrowth and stabilization, and discusses the cost and preparation of RU58841.

Verteporfin is discussed as a potential treatment for scarring alopecia. Minoxidil is suggested as an alternative treatment.

A group buy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.

The user has been using oral minoxidil, finasteride, and dutasteride to prevent hair loss, despite not showing significant balding. Many commenters believe the treatment is excessive, while some support early prevention.

A 22-year-old is experiencing hair loss after transitioning from fem HRT to DIY testosterone therapy and is considering using Dutasteride while also taking Saw Palmetto. They are concerned about the impact on virilization and proper development.

The conversation discusses hair loss treatments, specifically asking about clinics in the US that perform dutasteride mesotherapy. Minoxidil, finasteride, and RU58841 are also mentioned.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

The user switched to dutasteride in October 2023 and began taking oral minoxidil in June 2023, after using topical minoxidil for two years and microneedling for a year. They stopped using RU58841 due to side effects and are considering adding topical finasteride.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.